0001237899-20-000039.txt : 20200831
0001237899-20-000039.hdr.sgml : 20200831
20200831163749
ACCESSION NUMBER: 0001237899-20-000039
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200827
FILED AS OF DATE: 20200831
DATE AS OF CHANGE: 20200831
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAROSA JOSEPH J
CENTRAL INDEX KEY: 0001238303
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 201151951
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-08-27
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001238303
LAROSA JOSEPH J
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP General Counsel and Secret
Common Stock
2020-08-27
4
M
0
6000
52.03
A
20438
D
Common Stock
2020-08-27
4
F
0
3197
614.87
D
17241
D
Common Stock
2020-08-27
4
M
0
4000
52.03
A
21241
D
Common Stock
2020-08-27
4
F
0
2131
614.87
D
19110
D
Common Stock
2020-08-31
4
S
0
4672
615.04
D
14438
D
Common Stock
287
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
52.03
2020-08-27
4
M
0
6000
0.0
D
2021-12-16
Common Stock
6000
4000
D
Non-Qualified Stock Option (right to buy)
52.03
2020-08-27
4
M
0
4000
0.0
D
2021-12-16
Common Stock
4000
0
D
Represents volume-weighted average price of sales of 4,672 shares of Company stock on August 31, 2020 at prices ranging from $615.00 to $615.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price.
With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.
/s/**Joseph J. LaRosa
2020-08-31